Viewing data from:

ZILRETTA

NDA

TRIAMCINOLONE ACETONIDE | N208845 | PACIRA PHARMACEUTICALS INC

1 strength2 unique patents0 unique exclusivities

Patent Timeline

2 unique patents by expiration date

Active (2)Today

2027

2028

2029

2030

2031

Today

8828440

Aug. 4, 2031

9555048

Aug. 4, 2031

PTAB Proceedings

No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board

Patent Reexaminations

No ex parte or inter partes reexamination proceedings found at USPTO

Hatch-Waxman Litigation

No ANDA patent litigation cases (NOS 835) matched from PACER

Citizen Petitions

No FDA citizen petitions matched from Regulations.gov

Clinical Trials

159 trials from ClinicalTrials.gov — 12 recruiting, 2 active, 93 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields NCT04469075	Phase 2	Active	Memorial Sloan Kettering Cancer Center	48	2020-07-09 → 2027-07
Corticosteroid Meniscectomy Randomized Trial NCT04641351	Phase 4	Active	The Cleveland Clinic	150	2021-05-27 → 2027-08-01
Carbon Dioxide Laser-Assisted Delivery of Triamcinolone With or Without 5-Fluorouracil for Hypertrophic Burn Scars NCT07660120	N/A	Not Yet Recruiting	University of California, Davis	65	2026-08-22 → 2028-07-10
Efficacy of Clobetasol Vs Intralesional Triamcinolone in Lichen Planus Treatment NCT07666620	Phase 4	Not Yet Recruiting	Noor Aziz	50	2026-10-01 → 2027-04-30
Management of Postoperative Complications After Mandibular Third Molar Extraction Using Submucosal Triamcinolone Injection, Kinesiology Taping, and Standard Care NCT07719270	N/A	Not Yet Recruiting	Allama Iqbal Medical College	60	2027-01-01 → 2029-01-01
Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes NCT07757464	Phase 1/2	Not Yet Recruiting	Shifa International Hospital	125	2026-08-10 → 2027-01-30
Dropless Pars Plana Vitrectomy Study NCT05331664	Phase 4	Recruiting	Massachusetts Eye and Ear Infirmary	168	2022-07-25 → 2027-01-30
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study NCT02025023	Phase 3	Recruiting	University of Washington	120	2013-12 → 2026-07
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study NCT04207931	Phase 4	Recruiting	Wake Forest University Health Sciences	250	2018-04-30 → 2027-03
Triamcinolone Nanocapsules After Endoscopic Nasal Surgery NCT07714525	Phase 2	Recruiting	Deraya University	50	2026-05-01 → 2027-06-01

Source: ClinicalTrials.gov. Trials matched by ingredient name; data refreshed each weekday and may lag the registry.

VA Federal Supply Schedule

Government-negotiated contract prices | 2 NDCs (1 FSS, 1 Big4)

Lowest Price

$420.95

Highest Price

$615.07

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
65250-0003-01ZILRETTA 32MG/VIL INJ,SUSP,SA	$420.95	Big4	Pacira Therapeutics, Inc.	08/31/2029
65250-0003-01ZILRETTA 32MG/VIL INJ,SUSP,SA	$615.07	FSS	Pacira Therapeutics, Inc.	08/31/2029

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Zilretta (2024)

Total Spending

$1.9M

Total Claims

2,092

Beneficiaries

1,377

Avg Cost/Unit

$644.02

Spending Trend

$14K(2019)→$78K(2020)→$223K(2021)→$386K(2022)→$683K(2023)→$1.9M(2024)

YoY Change:-1.1%

5yr CAGR:-1.1%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

Medicare Part B Spending

CMS physician-administered drug spending for Zilretta (2024)

Total Spending

$64.8M

Total Claims

90,238

Beneficiaries

51,173

ASP Price

$17.65

Spending Trend

$37.3M(2019)→$51.7M(2020)→$63.9M(2021)→$62.8M(2022)→$62.2M(2023)→$64.8M(2024)

YoY Change:+3.7%

5yr CAGR:-1.5%

HCPCS: J3304 — Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg

Source: CMS Medicare Part B Spending by Drug (2024). Shows physician-administered drug costs.

API Supply Chain12 active DMFs15 inactive

11 active API suppliers hold Drug Master Files for this ingredient.

TAPI NL BVTRIAMCINOLONE ACETONIDE

DMF 47121982

FARMABIOS SPATRIAMCINOLONE ACETONIDE

DMF 146932000

TIANJIN TIANYAO PHARMACEUTICALS CO LTDTRIAMCINOLONE ACETONIDE USP

DMF 190962006

CURIA SPAIN SAUTRIAMCINOLONE ACETONIDE STERILE MICRONIZED, USP

DMF 211732007

SYMBIOTEC PHARMALAB PRIVATE LTDTRIAMCINOLONE ACETONIDE USP

DMF 212632008

FARMABIOS SPATRIAMCINOLONE ACETONIDE MICRONIZED STERILE

DMF 215912008

EUROAPI FRANCETRIAMCINOLONE ACETONIDE

DMF 229472009

NEWCHEM SPATRIAMCINOLONE ACETONIDE MICRONIZED

DMF 245432011

CORAL DRUGS PRIVATE LTDTRIAMCINOLONE ACETONIDE

DMF 313572017

SHANDONG SIRUI PHARMACEUTICAL CO LTDTRIAMCINOLONE ACETONIDE

DMF 363132022

ZHEJIANG XIANJU PHARMACEUTICAL CO LTDTRIAMCINOLONE ACETONIDE

DMF 398652024

HENAN LIHUA PHARMACEUTICAL CO LTDTRIAMCINOLONE ACETONIDE

DMF 398972024

ANTIBIOTICOS SPAInactiveTRIAMCINOLONE ACETONIDE

DMF 26511976

PIERREL SPAInactiveTRIAMCINOLONE ACETONIDE

DMF 26551976

MANUFACTURING ENTERPRISES INCInactiveTRIAMCINOLONE ACETONIDE 10%

DMF 27251976

ER SQUIBB AND SONS INCInactiveTRIAMCINOLONE ACETONIDE CONCENTRATE

DMF 27411976

GYMA LABORATORIES AMERICA INCInactiveTRIAMCINOLONE ACETONIDE

DMF 29491977

DIOSYNTH BVInactiveTRIAMCINOLONE ACETONIDE MICRO

DMF 37631980

CHEMSERVICES INCInactiveTRIAMCINOLONE ACETONIDE, USP IN THE EAST HANOVER, NJ FACILITIES

DMF 37951980

ROUSSELL UCLAFInactiveTRIAMCINOLONE ACETONIDE

DMF 40851981

COMPANIA ESPANOLA DE SINTESIS QUIMICA SAInactiveTRIAMCINOLONE ACETONIDE USPXX

DMF 41971981

FARMABOISInactiveTRIAMCINOLONE ACETONIDE

DMF 49571983

HOECHST MARION ROUSSEL SAInactiveTRIAMCINOLONE ACETONIDE

DMF 63671986

QUATRUMInactiveTRIAMCINOLONE ACETONIDE

DMF 64971986

PFIZER INCInactiveTRIAMCINOLONE ACETONIDE

DMF 88211990

NANOSYSTEMSInactiveTRIAMCINOLONE ACETONIDE NANOCRYSTAL COLLOIDAL DISPERSION

DMF 121811996

TEVA PHARMACEUTICAL INDUSTRIES LTDInactiveTRIAMCINOLONE ACETONIDE MICRONIZED STERILE

DMF 216582008

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

5 letters from Drugs@FDA

Date	Submission	Document
Dec 4, 2024	SUPPL -21	View Letter (PDF)
Sep 6, 2024	SUPPL -19	View Letter (PDF)
Dec 3, 2020	SUPPL -11	View Letter (PDF)
Dec 26, 2019	SUPPL -7	View Letter (PDF)
Oct 12, 2017	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 32MG/VIAL

RLD

2 patents0 exclusivities▴

FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR | Approved: Oct 6, 2017

Patents (2) · 1 use code

Patent #	Expiration	PED	Drug Substance	Drug Product	Use Code	Delist
8828440	Aug 4, 2031	—	—	Yes	—	—
9555048	Aug 4, 2031	—	—	—		—